Switching from originator infliximab to biosimilar infliximab in Japanese patients with rheumatoid arthritis achieving clinical remission (the IFX-SIRIUS study I): Study protocol for an interventional, multicenter, open-label, single-arm and noninferiority clinical trial with clinical, ultrasound, and biomarker assessments.

MLA

Shin-ya Kawashiri, et al. “Switching from Originator Infliximab to Biosimilar Infliximab in Japanese Patients with Rheumatoid Arthritis Achieving Clinical Remission (the IFX-SIRIUS Study I): Study Protocol for an Interventional, Multicenter, Open-Label, Single-Arm and Noninferiority Clinical Trial with Clinical, Ultrasound, and Biomarker Assessments.” Medicine, vol. 99, no. 30, July 2020, pp. 1–7. EBSCOhost, https://doi.org/10.1097/MD.0000000000021151.

APA

Shin-ya Kawashiri, Toshimasa Shimizu, Shuntaro Sato, Shimpei Morimoto, Yurika Kawazoe, Remi Sumiyoshi, Naoki Hosogaya, Chizu Fukushima, Hiroshi Yamamoto, Atsushi Kawakami, Kawashiri, S.-Y., Shimizu, T., Sato, S., Morimoto, S., Kawazoe, Y., Sumiyoshi, R., Hosogaya, N., Fukushima, C., Yamamoto, H., & Kawakami, A. (2020). Switching from originator infliximab to biosimilar infliximab in Japanese patients with rheumatoid arthritis achieving clinical remission (the IFX-SIRIUS study I): Study protocol for an interventional, multicenter, open-label, single-arm and noninferiority clinical trial with clinical, ultrasound, and biomarker assessments. Medicine, 99(30), 1–7. https://doi.org/10.1097/MD.0000000000021151

Chicago

Shin-ya Kawashiri, Toshimasa Shimizu, Shuntaro Sato, Shimpei Morimoto, Yurika Kawazoe, Remi Sumiyoshi, Naoki Hosogaya, et al. 2020. “Switching from Originator Infliximab to Biosimilar Infliximab in Japanese Patients with Rheumatoid Arthritis Achieving Clinical Remission (the IFX-SIRIUS Study I): Study Protocol for an Interventional, Multicenter, Open-Label, Single-Arm and Noninferiority Clinical Trial with Clinical, Ultrasound, and Biomarker Assessments.” Medicine 99 (30): 1–7. doi:10.1097/MD.0000000000021151.